Canan Dirican, Resident Physician at New York Medical College, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“I am pleased to share our newly published study evaluating racial and ethnic representation in mCRPC clinical trials.
Key findings:
- Across 33 phase III/IV trials (28,746 participants), only 3.8% of participants were Black
- Hispanic participation averaged just 6.7%
- Black enrollment declined from 13.7% -> 3% over time
- Only 73% of trials reported race; only 42% reported ethnicity
- Trial sites clustered in North America & Europe, none in Africa or the Caribbean
These gaps have real consequences for equity, access, and the generalizability of prostate cancer therapies.
We hope this work supports ongoing efforts to improve reporting, broaden trial geography, and design studies that reflect the populations most affected.”
Title: Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action
Authors: Canan D. Dirican, Sagar Patel, Anas Al Mardini, Amara Sofia, Bolivia Aloysia Crocete Fernandes, Venkatesh Gondhi, Michael Maroules
Read the Full Article on JCO Oncology Practice
More posts featuring Prostate Cancer.